Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald J Mattson

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|September 4, 2007
Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitorH Dalton King, Derek J Denhart, Jeffrey A Deskus, et al.
Journal of Medicinal Chemistry|June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
Journal of Medicinal Chemistry|December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonistRichard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agentsJeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.
Journal of Medicinal Chemistry|June 26, 2009
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Argyrios G Arvanitis, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|September 4, 2007
Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitorH Dalton King, Derek J Denhart, Jeffrey A Deskus, et al.
Journal of Medicinal Chemistry|June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.
Journal of Medicinal Chemistry|December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonistRichard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.
Bioorganic & Medicinal Chemistry Letters|September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agentsJeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.
Journal of Medicinal Chemistry|June 26, 2009
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Argyrios G Arvanitis, et al.
Pageof 3